Apyx Medical Corporation
Apyx Medical Corporation (APYX): 4 pipeline candidates · ~201 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
200.5 months
D/E 3.89 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for Apyx Medical Corporationacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$176.7M
Cash
$31.1M
Quarterly Burn
$572K
Runway
200.5 mo
Revenue
$12.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| ayon | Preclinical |
| renuvion | Approved |
| renuvion apr | Approved |
| renuvion micro | Approved |
Frequently asked questions
How many drug candidates are in Apyx Medical Corporation's pipeline?
Apyx Medical Corporation (APYX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Apyx Medical Corporation's lead drug candidate?
Apyx Medical Corporation's most advanced tracked candidate is ayon (Preclinical) for Body contouring, fat removal, tissue contraction, and aesthetic enhancement.
What is Apyx Medical Corporation's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Apyx Medical Corporation has approximately 200.5 months of cash runway.
What is Apyx Medical Corporation's market capitalization?
Apyx Medical Corporation's market capitalization is approximately $176.7M.
Who is the CEO of Apyx Medical Corporation?
Mr. Charles D. Goodwin II is the chief executive officer of Apyx Medical Corporation (APYX).
Get the full picture on Apyx Medical Corporation
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.